Literature DB >> 7561030

Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.

J C Hurtado1, S H Kim, K E Pollok, Z H Lee, B S Kwon.   

Abstract

The expression of the murine T cell Ag 4-1BB, a member of the TNF-R family, is induced by T cell activation. Previously, we and others had shown that signaling through 4-1BB enhanced proliferative T cell responses. To investigate a potential role for the interaction of 4-1BB with its ligand (4-1BBL) in T cell activation, we studied the ability of a soluble chimera of 4-1BB (4-1BBFc) to interfere with proliferative responses and cytokine production in models of activation dependent in intercellular interactions. The potential blocking effect of 4-1BBFc was compared with that of the chimeric molecule CTLA-4Ig, a reagent known to interfere with the interaction of CD28 (and/or CTLA-4) with B7 costimulatory receptors. In this study, we report that 4-1BBFc partially blocked both the activation of unfractionated splenocytes triggered by soluble anti-CD3 (anti-CD3s), and the more physiologically relevant responses to alloantigen. In addition, we show that both chimeric molecules partially blocked proliferative responses and IL-2 secretion by highly purified resting T cells activated with anti-CD3s in the presence of fixed accessory cells that express B7 receptors and 4-1BBL. Furthermore, in this model system, the blocking capacity of 4-1BBFc and CTLA-4Ig appears to correlate with the relative expression of their respective cognate receptors (4-1BBL and B7) on the accessory cell. Simultaneous addition of both blocking reagents produced an additive effect in the model systems studied.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561030

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.

Authors:  Kwang-Mi Kim; Ho Won Kim; Jae-Ouk Kim; Kyoung-Min Baek; Joong Gon Kim; Chang-Yuil Kang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.

Authors:  Kailin Xu; Chaohong Li; Xiuying Pan; Bing Du
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

3.  Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model.

Authors:  Elizabeth W Newcomb; Yevgeniy Lukyanov; Noriko Kawashima; Michelle Alonso-Basanta; Shu-Chi Wang; Mengling Liu; Maria Jure-Kunkel; David Zagzag; Sandra Demaria; Silvia C Formenti
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

4.  Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant.

Authors:  Jung D Kim; Chang H Kim; Byoung S Kwon
Journal:  Mol Cells       Date:  2011-01-11       Impact factor: 5.034

Review 5.  Review article: molecular signals and genetic reprogramming in peripheral T-cell differentiation.

Authors:  A Noble
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

6.  A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis.

Authors:  G Nocentini; L Giunchi; S Ronchetti; L T Krausz; A Bartoli; R Moraca; G Migliorati; C Riccardi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

7.  The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model.

Authors:  Kritika Kachapati; David E Adams; Yuehong Wu; Charles A Steward; Daniel B Rainbow; Linda S Wicker; Robert S Mittler; William M Ridgway
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

8.  4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation.

Authors:  Beom K Choi; Do Y Lee; Don G Lee; Young H Kim; Seon-Hee Kim; Ho S Oh; Chungyong Han; Byoung S Kwon
Journal:  Cell Mol Immunol       Date:  2016-03-14       Impact factor: 11.530

Review 9.  A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

10.  4-1BB enhances proliferation of beryllium-specific T cells in the lung of subjects with chronic beryllium disease.

Authors:  Douglas G Mack; Allison K Lanham; Brent E Palmer; Lisa A Maier; Tania H Watts; Andrew P Fontenot
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.